20599-01-3

Basic information

• Product Name: 2,2-Bis(broMoMethyl)-1,3-dioxolane
• Synonyms: 2,2-Bis(broMoMethyl)-1,3-dioxolane
• CAS NO: 20599-01-3
• Molecular Formula: C₅H₈Br₂O₂
• Molecular Weight: 259.92382
• Mol File: 20599-01-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 26 °C
• Boiling Point: 261.2°Cat760mmHg
• Flash Point: 103.2°C
• Appearance: /
• Density: 1.887g/cm³
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: 2,2-Bis(broMoMethyl)-1,3-dioxolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Bis(broMoMethyl)-1,3-dioxolane(20599-01-3)
• EPA Substance Registry System: 2,2-Bis(broMoMethyl)-1,3-dioxolane(20599-01-3)

Safety Data

• Hazardous Substances Data: 20599-01-3(Hazardous Substances Data)

Usage

General Description

2,2-bis(bromomethyl)-1,3-dioxolane is a chemical compound with the molecular formula C5H8Br2O2. It is a colorless liquid that is primarily used as a crosslinking agent in the production of polymers, such as epoxy resins and polyurethane. The compound is considered to be a halogenated organic compound and is classified as a hazardous substance due to its potential to cause skin and eye irritation. It is also known to be a potential environmental hazard and should be handled and disposed of with caution. The compound is commercially available and is used in various industrial applications, including as a building block for the synthesis of other organic compounds.

InChI:InChI=1/C5H8Br2O2/c6-3-5(4-7)8-1-2-9-5/h1-4H2

Upstream product

• 816-39-7 1,3-dibromoroacetone 
• 107-21-1 ethylene glycol 
• 67-64-1 acetone 
• 7381-30-8 2,2,7,7-tetramethyl-3,6-dioxa-2,7-disilaoctane 

Downstream Products

• 1227958-64-6 2-(4-bromophenyl)-5,8-dioxaspiro[3.4]octane-2-carbonitrile 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 

Relevant articles and documents

Diastereomeric Right- and Left-Handed Helical Structures with Fourteen (R)-Chiral Centers

The relationship between chiral centers and the helical-screw control of their peptides has already been reported, but it has yet to be elucidated in detail. A chiral four-membered ring α,α-disubstituted α-amino acid with a (R,R)-butane-2,3-diol acetal moiety at the γ-position, but no α-chiral carbon, was synthesized. X-ray crystallographic analysis unambiguously revealed that its homo-chiral heptapeptide formed right-handed (P) and left-handed (M) 310-helical structures at a ratio of 1:1. They appeared to be enantiomeric at the peptide backbone, but diastereomeric with fourteen (R)-configuration chiral centers. Conformational analyses of homopeptides in solution also indicated that diastereomeric (P) and (M) helices existed at approximately equal amounts, with a slight preference toward right-handedness, and they quickly interchanged at room temperature. The circumstances of chiral centers are important for the control of their helical-screw direction.

Preparation method of baricitinib

The invention discloses a preparation method of baricitinib and belongs to the technical field of drug preparation. The method comprises that 4-chloropyrrolopyrimidine as a starting raw material is subjected to amino protection, the product, hydrazine hydrate and acrolein undergo a one-pot displacement reaction and a cyclization reaction to produce an intermediate 4, a starting raw material 1, 3-dibromoacetone and ethylene glycol undergo a condensation reaction to produce an intermediate 5, the intermediate 5 and ethyl sulfonamide undergo a condensation reaction to produce an intermediate 6, the intermediate 6 and diethyl cyanomethylphosphonate undergo a reaction under action of a strong base to produce an intermediate 7, the intermediate 4 and the intermediate 7 undergo an addition reaction under the action of a catalyst, and the product undergoes a deprotection reaction to produce a desired product 1. The preparation method needs mild reaction conditions. The intermediate purification method is simple and easy, has a total yield of 40-55% and is suitable for industrial production.

NOVEL PHOSPHODI ESTERASE INHIBITORS

The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further re